Repositorio UFRO · Omeka S

Licochalcone A: A Potential Multitarget Drug for Alzheimer's Disease Treatment

Primer Autor	Olloquequi, Jordi
Co-autores	Ettcheto, Miren Cano, Amanda Fortuna, Ana Bicker, Joana Sanchez-Lopez, Elena Paz, Cristian Urena, Jesus Verdaguer, Ester Auladell, Carme Camins, Antoni
Título	Licochalcone A: A Potential Multitarget Drug for Alzheimer's Disease Treatment
Editorial	MDPI
Revista	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Lenguaje	en
Resumen	Licochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. While the Glycyrrhiza species has shown promise in treating various diseases such as cancer, obesity, and skin diseases due to its active compounds, the investigation of Licochalcone A's effects on the central nervous system and its potential application in Alzheimer's disease (AD) treatment have garnered significant interest. Studies have reported the neuroprotective effects of Lico-A, suggesting its potential as a multitarget compound. Lico-A acts as a PTP1B inhibitor, enhancing cognitive activity through the BDNF-TrkB pathway and exhibiting inhibitory effects on microglia activation, which enables mitigation of neuroinflammation. Moreover, Lico-A inhibits c-Jun N-terminal kinase 1, a key enzyme involved in tau phosphorylation, and modulates the brain insulin receptor, which plays a role in cognitive processes. Lico-A also acts as an acetylcholinesterase inhibitor, leading to increased levels of the neurotransmitter acetylcholine (Ach) in the brain. This mechanism enhances cognitive capacity in individuals with AD. Finally, Lico-A has shown the ability to reduce amyloid plaques, a hallmark of AD, and exhibits antioxidant properties by activating the nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant defense mechanisms. In the present review, we discuss the available findings analyzing the potential of Lico-A as a neuroprotective agent. Continued research on Lico-A holds promise for the development of novel treatments for cognitive disorders and neurodegenerative diseases, including AD. Further investigations into its multitarget action and elucidation of underlying mechanisms will contribute to our understanding of its therapeutic potential.
Fecha Publicación	2023
Tipo de Recurso	artículo de revisión
doi	10.3390/ijms241814177
Formato Recurso	PDF
Palabras Claves	neurodegeneration cognitive enhancement multi-target therapy
Ubicación del archivo	http://dx.doi.org/10.3390/ijms241814177
Categoría OCDE	Bioquímica y biología molecular Química
Materias	neurodegeneración mejora cognitiva terapia multiobjetivo
Identificador del recurso (Mandatado-único)	artículo de revisión
Versión del recurso (Recomendado-único)	versión publicada
License	CC BY 4.0
Condición de la licencia (Recomendado-repetible)	CC BY 4.0
Derechos de acceso	acceso abierto
Access Rights	acceso abierto
Id de Web of Science	WOS:001073766300001
ISSN	1661-6596
Tipo de ruta	verde# dorado
Categoría WOS	Bioquímica y biología molecular Química
Referencia del Financiador (Mandatado si es aplicable-repetible)	MICINN PID2021-123462OB-I00 MICINN PID2021-122473OA-I00 GENCAT 2021 SGR 00288 CIBERNED CB06/05/2004 PI2021/03 FCT 127303 ISCIII CD22/00125 ADEY INUB CEX2021-001159-M